



20.03.2023

08:55 - 09:00 **Type: Opening session** **Hall A**
Title: Opening session

Moderation: Jean-Yves Blay, France; Judith Bovée, Netherlands; Robin Jones, United Kingdom

08:55 - 09:00 **Welcome to the ESMO Sarcoma and Rare Cancers Congress 2023**

Jean-Yves Blay¹; Judith Bovée²; Robin Jones³, ¹Centre Léon Bérard, Lyon, France, ²LUMC-Leiden University Medical Center, Leiden, Netherlands, ³The Royal Marsden Hospital - Chelsea, London, United Kingdom

09:00 - 10:20 **Type: Educational session** **Hall A**
Title: Evolving classification of sarcomas

Moderation: Judith Bovée, Netherlands; Christopher Fletcher, United States of America

09:00 - 09:05 **Introduction**

09:05 - 09:20 **New bone and soft tissue tumour entities**

Judith Bovée, LUMC-Leiden University Medical Center, Leiden, Netherlands

09:20 - 09:35 **WGS and molecular risk factors for sarcomas**

David Thomas, Garvan Institute of Medical Research, Darlinghurst, Australia

09:35 - 09:50 **NGS for sarcoma diagnostics**

Christopher Fletcher, Brigham and Women's Hospital, Boston, United States of America

09:50 - 10:05 **Proteomics and sarcomas**

Paul Huang, ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, United Kingdom

10:05 - 10:20 **Q&A and discussion**



09:00 - 10:20	Type: Educational session Title: Improving the continuum of care in rare gynaecological and genitourinary oncology Moderation: Isabelle Ray-Coquard, France; Jourik Gietema, Netherlands	Hall B1
09:00 - 09:05	Introduction	
09:05 - 09:20	Rare non epithelial ovarian tumours <u>Domenica Lorusso</u> , Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, Italy	
09:20 - 09:35	How national or supra national organization can change the management and improve the prognosis <u>Isabelle Ray-Coquard</u> , Centre Léon Bérard, Lyon, France	
09:35 - 09:50	Non-germ cell malignancies arising in teratoma: New developments in treatment strategies <u>Darren Feldman</u> , Memorial Sloan Kettering Cancer Center, New York, United States of America	
09:50 - 10:05	Late effects of treatment for testicular cancer with a focus on cancer survivors <u>Hege Sagstuen-Haugnes</u> , University Hospital of North Norway, Tromso, Norway	
10:05 - 10:20	Q&A and discussion	



09:00 - 10:20	Type: Educational session Title: Rare cancers and tumour agnostic oncology Moderation: Paolo G. Casali, Italy; Annalisa Trama, Italy	Hall B3
09:00 - 09:05	Introduction: Rare cancers and rare subgroups of common cancers	
09:05 - 09:20	An appraisal of current agnostic medical oncology in common and rare solid cancers <u>Claudia María Valverde Morales</u> , Vall d'Hebron University Hospital, Barcelona, Spain	
09:20 - 09:35	New trials for agnostic medical oncology <u>Denis Lacombe</u> , EORTC AISBL/IVZW - European Organisation for Research and Treatment of Cancer, Brussels, Belgium	
09:35 - 09:50	Towards an agnostic medical taxonomy? <u>Christoph Benedikt Westphalen</u> , LMU Klinikum der Universität München, Munich, Germany	
09:50 - 10:05	EMA vis-à-vis agnostic oncology <u>Francesco Pignatti</u> , European Medicines Agency - Amsterdam, Amsterdam, Netherlands	
10:05 - 10:20	Q&A and discussion	
10:20 - 10:50	Type: Coffee break Title: Coffee break	Foyer (Ground floor)



10:50 - 12:10	Type: Educational session Title: Ultra rare sarcomas Moderation: Silvia Stacchiotti, Italy; Robert Cusimano, Canada	Hall A
10:50 - 10:55	Introduction	
10:55 - 11:10	Collaboration and interaction with regulatory authorities <u>Silvia Stacchiotti</u> , Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy	
11:10 - 11:25	Streamlining clinical trials in ultra rare sarcomas <u>William D. Tap</u> , MSKCC - Memorial Sloan Kettering Cancer Center, New York, United States of America	
11:25 - 11:40	Cardiac transplantation strategies for cardiac sarcomas <u>Robert Cusimano</u> , University of Toronto - St. George Campus, Toronto, Canada	
11:40 - 11:55	Low grade fibromyxoid sarcoma: Paediatric vs adult oncology perspectives <u>Winette Van Der Graaf</u> , NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands	
11:55 - 12:10	Q&A and discussion	



10:50 - 12:10 **Type: Educational session** **Hall B3**
Title: Non-skin melanoma, adnexal tumours and Merkel cell carcinoma
 Moderation: Ellen Kapiteijn, Netherlands; Sophie Piperno-Neumann, France

10:50 - 10:55 **Introduction**

10:55 - 11:10 **New developments in the treatment of uveal melanoma**

Sophie Piperno-Neumann, Institut Curie, Paris, France

11:10 - 11:25 **Towards improvement of outcomes in mucosal melanoma**

Ellen Kapiteijn, Leiden University Medical Center (LUMC), Leiden, Netherlands

11:25 - 11:40 **Very rare: Adnexal tumors**

Stefano Cavaliere, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, Italy

11:40 - 11:55 **Treatment of Merkel cell carcinoma in the 21th century**

Iwona Lugowska, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

11:55 - 12:10 **Q&A and discussion**

10:50 - 12:10 **Type: Abstract related session** **Hall B1**
Title: Proffered paper session - Rare Cancers
 Moderation: Michael Seckl, United Kingdom; Antonia Digkila, Switzerland

10:50 - 11:00 **130 - Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé; study including 469 patients: A TMRG and GINECO group study**

B. Hanvic¹; F. Lecuru²; H. Vanacker¹; P. Pautier³; F. Narducci⁴; F. Cherifi⁵; A. Floquet⁶; M.A. Angeles⁷; D. Berton-Rigaud⁸; C. Pomel⁹; E. Kalbacher¹⁰; M. Provansal Gross¹¹; Y. Fernandez¹²; T. De La Motte Rouge¹³; F. Selle¹⁴; P. Meeus¹; C. Genestie³; J. Salleron¹²; Isabelle Ray-Coquard¹, ¹Centre Léon Bérard, Lyon, France, ²Institut Curie, Paris, France, ³Institut Gustave Roussy, Villejuif, Cedex, France, ⁴Centre Oscar Lambret, Lille, France, ⁵Centre Francois Baclesse, Caen, France, ⁶Institute Bergonié, Bordeaux, France, ⁷IUCT - Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France, ⁸ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, France, ⁹Université Auvergne, Clermont-Ferrand, France, ¹⁰CHRU Besancon - Hopital Jean Minjoz, Besancon, France, ¹¹Institute Paoli Calmettes, Marseille, France, ¹²Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, France, ¹³Centre Eugene - Marquis, Rennes, France, ¹⁴Groupe Hospitalier Diaconesses Croix Saint Simon, Paris, France

11:00 - 11:07 **Invited discussant**



Michael Seckl, Charing Cross Hospital - Imperial College Healthcare NHS Trust, London, United Kingdom

- 11:07 - 11:17 **80 - Outcomes for patients with appendix adenocarcinoma and the role of systemic chemotherapy**
Madeleine Strach; B. Chakrabarty; R. Nagaraju; S. Mullamitha; M. Braun; S. O'Dwyer; O. Aziz; J. Barriuso, The Christie NHS Foundation Trust, Manchester, United Kingdom
- 11:17 - 11:24 **Invited discussant**
Antonia Digklia, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
- 11:24 - 11:34 **270 - Master gene regulation activity and methylation data reveals common patterns in well differentiated neuroendocrine tumors (NETs) from different tumor sites**
Carlos Carretero-Puche¹; B. Antón Pascual²; B. Gil-Calderón¹; M. Benavent³; L. Gomez-Izquierdo³; P. Jimenez-Fonseca⁴; A. Teijo²; Y. Rodríguez²; B. Rubio-Cuesta¹; G. Gomez-Lopez⁵; F. Al-Shahrour⁵; B. Soldevilla¹; R. Garcia-Carbonero⁶, ¹Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12) and CNIO, Madrid, Spain, ²Hospital 12 de Octubre, Madrid, Spain, ³Hospital Universitario Virgen del Rocío and IBIS, Seville, Spain, ⁴Hospital Universitario Central de Asturias, Oviedo, Spain, ⁵CNIO - Centro Nacional de Investigaciones Oncologicas, Madrid, Spain, ⁶Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CNIO, Hospital Universitario Doce de Octubre. Universidad Complutense de Madrid, Madrid, Spain
- 11:34 - 11:41 **Invited discussant**
Lynnette Fernandez-Cuesta, IARC - International Agency for Research on Cancer, Lyon, France
- 11:41 - 11:51 **220 - Sinonasal cancer: Molecular biomarkers for tumor classification and targeted treatment**
Mario Hermsen, Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain
- 11:51 - 11:58 **Invited discussant**
Alessandro Franchi, University of Pisa - DAM, Pisa, Italy
- 11:58 - 12:10 **Q&A**
- 12:10 - 13:10** **Type: Coffee break** **Foyer (Ground floor)**
Title: Lunch



12:15 - 13:00 **Type: Young Oncologists session** **Foyer (First floor)**
Title: YO Mentorships: Research in rare cancers
Moderation: Elizabeth Connolly, Australia; Pawel Sobczuk, Poland

12:15 - 12:15 **Setting up collaborations in rare cancers**
Silvia Stacchiotti, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

12:15 - 12:15 **Translational research in rare cancers**
David Thomas, Garvan Institute of Medical Research, Darlinghurst, Australia

12:15 - 12:15 **How to set up your first clinical trial**
Robin Jones, The Royal Marsden Hospital - Chelsea, London, United Kingdom

13:15 - 14:15 **Type: Controversy session** **Hall A**
Title: Is HTA (Health Technology Assessment) applicable to rare cancers?
Moderation: Annalisa Trama, Italy

13:15 - 13:25 **Introduction and first vote**
Annalisa Trama, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

13:25 - 13:45 **Pro**
Cesar Serrano, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, Spain

13:45 - 14:05 **Con**
Jean-Yves Blay, Centre Léon Bérard, Lyon, France

14:05 - 14:15 **Second vote and conclusions**
Annalisa Trama, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy



14:30 - 15:50	Type: Educational session Title: What to do after whoops surgery of soft tissue sarcoma (STS) Moderation: Alessandro Gronchi, Italy; Carol Swallow, Canada	Hall A
14:30 - 14:35	Introduction	
14:35 - 14:50	Dissecting R1 resections <u>Carol Swallow</u> , Mount Sinai Hospital, Toronto, Canada	
14:50 - 15:05	The radiation oncologist's perspective <u>Aisha Miah</u> , The Royal Marsden Hospital - Chelsea, London, United Kingdom	
15:05 - 15:20	Against re-operation <u>Alessandro Gronchi</u> , Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy	
15:20 - 15:35	In favour re-operation <u>Piotr Rutkowski</u> , Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland	
15:35 - 15:50	Q&A and discussion	



14:30 - 15:50	Type: Educational session Title: Management of GEP NENs Moderation: Rocio Garcia-Carbonero, Spain; Alfredo Berruti, Italy	Hall B1
14:30 - 14:35	Introduction	
14:35 - 14:50	Tips and tricks for the diagnosis and treatment of hormonal syndromes <u>Simona Glasberg</u> , Hadassah University Hospital - Ein Kerem, Jerusalem, Israel	
14:50 - 15:05	The theranostic revolution: Current and future perspectives in the field of NENs <u>Andreas Kjaer</u> , Rigshospitalet, Copenhagen, Denmark	
15:05 - 15:20	Optimal treatment sequence in advanced pancreatic NETs: What have we learnt from recent trials? <u>Rocio Garcia-Carbonero</u> , University Hospital 12 De Octubre, Madrid, Spain	
15:20 - 15:35	Management of advanced extrapulmonary NECs: Have we made any progress? <u>Jennifer Chan</u> , Dana Farber Cancer Institute, Boston, United States of America	
15:35 - 15:50	Q&A and discussion	



14:30 - 15:50	Type: Patient advocacy session Title: Sarcoma Patient Advocacy Global Network (SPAGN) session: Research for patient benefit Moderation: Gerard van Oortmerssen, Netherlands	Hall B3
14:30 - 14:50	The value of patient's input in sarcoma research <u>Winette Van Der Graaf</u> , NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands	
14:50 - 14:55	Q&A and discussion	
14:55 - 15:15	Value of the patient voice <u>Gerard Van Oortmerssen</u> , Contact Groep GIST, Naarden, Netherlands	
15:15 - 15:25	Value in patient involvement (pre-recorded) <u>Roger Wilson</u> , Sarcoma UK, London, United Kingdom	
15:25 - 15:45	From "patient expert" to "patient partner" throughout the research process (pre-recorded) <u>Ornella Gonzato</u> , Trust Paola Gonzato-Rete Sarcoma Onlus, Udine, Italy	
15:45 - 15:50	Q&A and discussion	
15:50 - 16:20	Type: Coffee break Title: Coffee break	Foyer (Ground floor)



16:20 - 17:40	Type: Educational session Title: The evolution of local/ablative therapeutic approaches in sarcomas Moderation: B. Ashleigh Guadagnolo, United States of America; Rick Haas, Netherlands	Hall A
16:20 - 16:25	Introduction	
16:25 - 16:40	Curative radiation therapy <u>Carmen Llacer</u> , ICM - Institut du Cancer de Montpellier, Montpellier, Cedex 5, France	
16:40 - 16:55	Proton beam and carbon ion <u>B. Ashleigh Guadagnolo</u> , MD Anderson Cancer Center, Houston, United States of America	
16:55 - 17:10	Intralesional radiotherapy/brachytherapy in sarcomas <u>Rick Haas</u> , NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands	
17:10 - 17:25	Cryotherapy of sarcoma <u>Afshin Gangi</u> , Hopitaux Universitaires de Strasbourg - Nouvel Hopital Civil, Strasbourg, France	
17:25 - 17:40	Q&A and discussion	



16:20 - 17:40	Type: Educational session Title: Managing patients with ultra rare thoracic and head neck tumours of ultra rare histologies Moderation: Christopher French, United States of America; Elena Colombo, Italy	Hall B1
16:20 - 16:25	Introduction	
16:25 - 16:40	Salivary gland adenoidcystic carcinoma: A complex entity <u>Renata Ferrarotto</u> , The University of Texas M. D. Anderson Cancer Center, Houston, United States of America	
16:40 - 16:55	Non adenoid cystic salivary gland carcinomas: Tips for precision approaches <u>Elena Colombo</u> , Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy	
16:55 - 17:10	NUT carcinoma of the lung <u>Christopher French</u> , Brigham and Women's Hospital, Boston, United States of America	
17:10 - 17:25	Rare NSCLC histologies <u>Diego Kauffmann-Guerrero</u> , LMU Klinikum der Universität München, Munich, Germany	
17:25 - 17:40	Q&A and discussion	



16:20 - 17:40	Type: Patient advocacy session Title: Patient advocacy on rare cancers Moderation: Paolo G. Casali, Italy; Ariane Weinman, France	Hall B3
16:20 - 16:25	Introduction: Patient advocacy as a key factor of advancement in rare cancers	
16:25 - 16:40	Welcome to our world... (pre-recorded) <u>Ornella Gonzato</u> , Trust Paola Gonzato-Rete Sarcoma Onlus, Udine, Italy	
16:40 - 16:55	Commonalities and differences between rare diseases and rare cancers <u>Ariane Weinman</u> , EURORDIS - European Organisation for Rare Diseases, Paris, France	
16:55 - 17:10	Practical patient advocates' engagement in the development of STARTER, a rare cancer registry <u>Emma Kinloch</u> , Salivary Gland Cancer UK, London, United Kingdom	
17:10 - 17:25	On the physician's side: Partnering with patients on rare cancers <u>Paolo G. Casali</u> , Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy	
17:25 - 17:40	Q&A and discussion	



21.03.2023

09:00 - 10:20 **Type: Educational session** **Hall A**
Title: Delving into the challenges of GIST heterogeneity
Moderation: Maria Pantaleo, Italy; Cesar Serrano, Spain

09:00 - 09:05 **Introduction**

09:05 - 09:20 **Mechanisms or resistance in GIST**

Sebastian Bauer, WTZ - Westdeutsches Tumorzentrum Essen, Essen, Germany

09:20 - 09:35 **SDH deficient GIST**

Neeltje Steeghs, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

09:35 - 09:50 **Quadruple negative GIST**

Maria Pantaleo, Policlinico Sant'Orsola-Malpighi, Bologna, Italy

09:50 - 10:05 **What are our next questions for GIST: New generation of inhibitors**

Cesar Serrano, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, Spain

10:05 - 10:20 **Q&A and discussion**



09:00 - 10:20	Type: Educational session Title: Challenges in diagnosis and treatment of rare gynaecological and genitourinary cancers Moderation: Patrizia Giannatempo, Italy; Isabelle Ray-Coquard, France	Hall B1
09:00 - 09:05	Introduction	
09:05 - 09:20	Genomic profiling and immunotherapy in penile cancer <u>Patrizia Giannatempo</u> , Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy	
09:20 - 09:35	Targeted treatment of renal cell cancer in hereditary syndromes <u>Ronan Flippot</u> , Institut Gustave Roussy, Villejuif, France	
09:35 - 09:50	Rare epithelial ovarian carcinoma: What can be different from HGSC <u>David Sp Tan</u> , NUHS - National University Health System, Singapore, Singapore	
09:50 - 10:05	Rare epithelial uterine carcinoma: How to make the difference <u>Alexandra Leary</u> , Institut Gustave Roussy, Villejuif, Cedex, France	
10:05 - 10:20	Q&A and discussion	



09:00 - 10:20	Type: Educational session Title: Health care networking in the EU about cancer and rare cancers Moderation: Tit Albreht, Slovenia; Paolo G. Casali, Italy	Hall B3
09:00 - 09:05	Introduction	
09:05 - 09:20	Health care networking as an item <u>Donata Meroni</u> , European Commission, Brussels, Belgium	
09:20 - 09:35	The European Reference Networks on rare cancers <u>Jean-Yves Blay</u> , Centre Léon Bérard, Lyon, France	
09:35 - 09:50	The EU National Comprehensive Cancer Network <u>Tit Albreht</u> , National Institute of Public Health of Slovenia - Nacionalni institut za javno zdravje, Ljubljana, Slovenia	
09:50 - 10:05	The EU Networks of Expertise <u>Paolo G. Casali</u> , Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy	
10:05 - 10:20	Q&A and discussion	
10:20 - 10:50	Type: Coffee break Title: Coffee break	Foyer (Ground floor)



10:50 - 12:10	Type: Educational session Title: STS2: Neoadjuvant and adjuvant chemotherapy Moderation: Bernd Kasper, Germany; Khin Thway, United Kingdom	Hall B1
10:50 - 10:55	Introduction	
10:55 - 11:10	Overview of neoadjuvant chemotherapy <u>Javier Martin-Broto</u> , Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain	
11:10 - 11:25	Positioning of adjuvant chemotherapy in current practice <u>Bernd Kasper</u> , UMM - Universitaetsklinikum Mannheim, Mannheim, Germany	
11:25 - 11:40	What is the optimal perioperative sequence of chemotherapy and radiotherapy <u>Antonia Digkila</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland	
11:40 - 11:55	Defining pathological response <u>Khin Thway</u> , The Royal Marsden Hospital - NHS Foundation Trust, London, United Kingdom	
11:55 - 12:10	Q&A and discussion	



10:50 - 12:10 **Type: Educational session** **Hall B3**
Title: State-of-the-art diagnosis and management of rare primary CNS tumours
Moderation: Ahmed Idbaih, France; Enrico Franceschi, Italy

10:50 - 10:55 **Introduction**
Ahmed Idbaih¹; Enrico Franceschi², ¹Hopital Pitié Salpêtrière AP-HP, Paris, France, ²IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy

10:55 - 11:10 **Rare glial, glioneuronal and neuronal tumours**
Ahmed Idbaih, Hopital Pitié Salpêtrière AP-HP, Paris, France

11:10 - 11:25 **Medulloblastoma**
Enrico Franceschi, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy

11:25 - 11:40 **Spinal cord tumours**
Elena Anghileri, Fondazione IRCCS - Istituto Neurologico C.Besta, Milan, Italy

11:40 - 11:55 **Intracranial germ cell tumours**
Cécile Faure-Contet, IHOPe - Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, France

11:55 - 12:10 **Q&A and discussion**

10:50 - 12:10 **Type: Abstract related session** **Hall A**
Title: Proffered paper session - Sarcoma
Moderation: Robin Jones, United Kingdom; Judith Bovée, Netherlands

10:50 - 11:00 **420 - A phase Ia/b, dose-escalation and expansion study evaluating the MDM2–p53 antagonist BI 907828 in patients with solid tumours: Safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS)**
Patrick Schoeffski¹; N. Yamamoto²; T. Bauer³; M. Patel⁴; P. Lorusso⁵; M. Lahmar⁶; S. Durland-Busbice⁷; J. Geng⁷; M. Gounder⁸, ¹Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium, ²National Cancer Center Hospital, Tokyo, Japan, ³Tennessee Oncology, Nashville, United States of America, ⁴Florida Cancer Specialists & Research Institute, Sarasota, United States of America, ⁵Yale Cancer Center, New Haven, United States of America, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁷Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, United States of America, ⁸Memorial Sloan Kettering Cancer Center, New York, United States of America

11:00 - 11:10 **430 - MDM2 inhibitor milademetan: Safety profile and management of adverse events (AEs)**
Chiara Fabbroni¹; R. Jones²; T. Linback³; E. Macneilly³; F. Xu³; L. Simeral⁴, ¹Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, Italy, ²The Royal Marsden Hospital - Chelsea, London, United Kingdom, ³Rain Oncology Inc, Newark, United States



of America, ⁴Pennsylvania Hospital, Philadelphia, United States of America

11:10 - 11:20 **440 - Comparison of clinical outcomes of patients with infantile fibrosarcoma (IFS) treated with larotrectinib in the SCOUT study versus historical cohort: The EPI-VITRAKVI study**

Daniel Orbach¹; L. Lemelle¹; M. Carton¹; S.K. Khadir²; M. Feuilly²; M. Kurtinecz³; C. Vokuhl⁴; E. Koscielniak⁵; G. Pierron¹; M. Sparber-Sauer⁵, ¹Institut Curie, Paris, France, ²Bayer Healthcare - France, Loos, France, ³Bayer HealthCare Pharmaceuticals Inc., Whippany, United States of America, ⁴Institute of Experimental Immunology - UKB University of Bonn, Bonn, Germany, ⁵Klinikum Stuttgart - Katharinenhospital (KH), Stuttgart, Germany

11:20 - 11:30 **Invited discussant**

Jean-Yves Blay, Centre Léon Bérard, Lyon, France

11:30 - 11:40 **450 - Clonal evolution of dedifferentiated liposarcoma**

Tetsuya Sekita¹; N. Asano²; T. Kubo¹; S. Mitani¹; N. Hattori¹; A. Yoshida³; E. Kobayashi¹; M. Komiyama¹; U. Toshikazu⁴; R. Nakayama²; A. Kawai¹; M. Nakamura²; H. Ichikawa¹, ¹NCCH - National Cancer Center Hospital-Tsukiji Campus, Chuo-ku, Japan, ²Keio University School of Medicine, Shinjuku-ku, Japan, ³National Cancer Center Research Institute - Tsukiji Campus, Chuo-ku, Japan, ⁴National Cancer Center Hospital, Tokyo, Japan

11:40 - 11:50 **460 - Integrated molecular analysis of human dedifferentiated liposarcoma identifies a population of tumoral progenitors vulnerable to TGF beta inhibition**

Sarah Watson; N. Gruel; C. Quignot; J. Vibert; S. Bonvalot; S. El Zein; D. Tzanis; S. Baulande; O. Mariani; J. Waterfall; O. Delattre, Institut Curie, Paris, France

11:50 - 12:00 **Invited discussant**

Eva Wardelmann, University Hospital Muenster-Gerhard Domagk Institute of Pathology, Muenster, Germany

12:00 - 12:10 **Q&A**

12:10 - 13:10 Type: Poster Display session Foyer (Ground floor)
Title: Poster display session

12:10 - 12:10 **Central Nervous System (CNS)**

12:10 - 12:10 **1P - Clinical characteristics and treatment outcomes for adult medulloblastoma: A tertiary cancer center experience**

Ayah Erjan; W. Asha; M. Alhussaini; M. Elayyan; A. Alshorbaji; A. Ibrahim; R. Amarin; N. Sarhan; T. Awabdeh; M. Obeidat; D. Abulaban; M. Alsughayer; A. Almousa, KHCC - King Hussein Cancer Center, Amman, Jordan



- 12:10 - 12:10 **2P - Long-term follow-up to the phase I/II study of CAN008 plus standard chemoradiotherapy treatment in patients with newly diagnosed glioblastoma multiforme**
Ian Yi-Feng Chang¹; H.-C. Tsai¹; C.-H. Chen¹; H.-C. Chen¹; Y.-Y. Lin²; C.-W. Huang¹; G.F. Cox³; F.-M. Huang⁴; K.-T. Chen⁵; Y.-J. Lin⁵; K.-C. Wei⁶, ¹Chang Gung University, Taoyuan City, Taiwan, ²Academia Sinica and National Taiwan University, Taipei, Taiwan, ³CANbridge Pharmaceuticals, Burlington, United States of America, ⁴CANbridge Pharmaceuticals - Shanghai Office, Shanghai, China, ⁵Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital, Taoyuan City, Taiwan, ⁶New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan
- 12:10 - 12:10 **3P - Bevacizumab plus irinotecan as second-line treatment of glioblastoma: Real-world evidence**
R. Ranchor; M.J. Ramos; R. Romao; A. Mendes; R. Pichel; J. Coelho; E. Rosendo; Manuel Magalhaes; A.M. Araújo, Centro Hospitalar Universitário do Porto, Porto, Portugal
- 12:10 - 12:10 **4P - FAT1: A novel modulator of autophagy in human glioblastoma**
Yakhlesh Gupta; N. Malik; S. Goswami; M. Arora; A. Kundu; S. Gupta; M. Kapoor; V. Suri; A. Suri; P. Chattopadhyay; S. Sinha; K. Chosdol, AIIMS - All India Institute of Medical Sciences, New Delhi, India
- 12:10 - 12:10 **5P - Long term outcome of surgical management for vertebral hemangioma presenting with myelopathy**
Pankaj Singh¹; S. Chandra²; S. Kale², ¹All India Institute of Medical Sciences, New Delhi, India, ²AIIMS - All India Institute of Medical Sciences, New Delhi, India
- 12:10 - 12:10 **6P - Patterns of treatment of patients with glioblastoma multiforme in the real world, a Mexican experience**
Raul Trejo Rosales¹; J. Sanchez Hernandez²; S. Zarroca Palacios²; V. Volante Facio²; Y.A. Remolina Bonilla¹, ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de Mexico, Mexico, ²UNAM - Universidad Nacional Autonoma de Mexico, Ciudad de Mexico, Mexico
- 12:10 - 12:10 **7P - Extracranial metastasis of CNS malignancies and medulloblastomas in particular in adult patients with a ventriculoperitoneal shunt: Review of the literature**
Vaia Mentessidou; D. Dionysopoulos; K. Lallas; E. Timotheadou, General Hospital Papageorgiou, Pavlos Melas, Greece
- 12:10 - 12:10 **Digestive cancers**
- 12:10 - 12:10 **9P - Epidemiology and characteristics of fibrolamellar hepatocellular carcinoma: An analysis of surveillance, epidemiology, and end results (SEER) database**
Muhammed Elfaituri, University of Tripoli, Tripoli, Libya
- 12:10 - 12:10 **10P - Molecular mutations in appendix cancers**



Madeleine Strach¹; B. Chakrabarty¹; R. Nagaraju¹; G. Burghel²; H. Schlecht²; S. Mullamitha¹; M. Braun¹; S. O'Dwyer¹; O. Aziz¹; J. Barriuso¹, ¹The Christie NHS Foundation Trust, Manchester, United Kingdom, ²GLH - The North West Genomic Laboratory Hub, Manchester, United Kingdom

12:10 - 12:10 **Genitourinary cancers**

12:10 - 12:10 **12P - Renal cancer metastasis patterns and racial disparities: SEER database population study 2010-2019**

Amro El-Sakka¹; A. Ellaithy²; A. Abo El Haj¹, ¹Suez Canal University, Ismailia, Egypt, ²Suez Canal University Hospital, Ismailia, Egypt

12:10 - 12:10 **Gynaecological cancers**

12:10 - 12:10 **14P - Unravelling the immune landscape of non-epithelial ovarian cancer**

Tina Laga¹; A.-S. Van Rompuy¹; P. Busschaert²; S. Olbrecht¹; L. Loverix¹; F. Lodi²; T. Baert³; T. Van Gorp⁴; I. Vergote¹; D. Lambrechts⁵; E. Van Nieuwenhuysen¹, ¹UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium, ²VIB-KU Leuven Center for Cancer Biology (CCB), Leuven, Belgium, ³UZ Leuven, Leuven, Belgium, ⁴University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium, ⁵KU Leuven, Leuven, Belgium

12:10 - 12:10 **15P - Clinicopathological characteristics and survival outcomes for PTSS and ETT: A population-based study**

Sakhr Alshwayyat¹; S. Zaitoun²; T. Abdulsalam¹; M. Al-Sous¹, ¹JUST - Jordan University of Science and Technology, Irbid, Jordan, ²Yarmouk University, Irbid, Jordan

12:10 - 12:10 **16P - Response to taxanes in low-grade serous ovarian cancer patients and cell lines**

Seema Kumari¹; T. Moujaber¹; I. Madsen¹; B. Gao²; P. Provan³; S. Srirangan¹; N. Bouantoun¹; C. Kennedy²; R. Sharma³; S. Fereday⁴; N. Traficante⁴; M. Friedlander⁵; A. Brand²; C. Gourley⁶; D. Garsed⁴; D. Bowtell⁴; R. Balleine¹; P. Harnett²; A. Defazio¹, ¹The Westmead Institute for Medical Research, Westmead, Australia, ²Westmead Hospital, Westmead, Australia, ³The University of Sydney, Sydney, Australia, ⁴Peter MacCallum Cancer Center, Melbourne, Australia, ⁵Prince of Wales Hospital - Nelune Comprehensive Cancer Centre, Sydney, Australia, ⁶Cancer Research UK Scotland Centre, Edinburgh, United Kingdom

12:10 - 12:10 **17P - Exploiting the immune-modulatory effects of PI3K/mTOR inhibitors to enhance response to immune-checkpoint blockade in uterine leiomyosarcoma**

Wout De Wispelaere¹; D. Annibali¹; S. Tuybaerts²; J. Messiaen¹; A. Antoranz¹; R. Baiden-Amissah³; T. Van Brussel¹; R. Schepers¹; G. Philips¹; B. Boeckx¹; M.F. Baietti¹; K.Y. Ho Wang Yin⁴; E. Bayon⁴; A.-S. Van Rompuy³; E. Leucci¹; S. Tabruyn⁴; F. Bosisio¹; D. Lambrechts¹; F. Amant³, ¹KU Leuven, Leuven, Belgium, ²UZ Brussel - Universitair



Ziekenhuis Brussel, Jette, Belgium, ³UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium, ⁴TransCure bioServices, Archamps, France

- 12:10 - 12:10 **18P - Malignant Brenner ovarian tumor: Fertility-sparing surgery versus radical hysterectomy**
Asmaa Ellaithy, Suez Canal University, Ismailia, Egypt
- 12:10 - 12:10 **19P - Long term sexual disorders among rare ovarian cancer survivors: The national GINECO case-control Vivrovaire Rare Tumors study**
Coraline Dubot¹; F. Joly Lobbedez²; I. Ray Coquard³; A. Floquet⁴; S. Lefevre Arbogast¹; F. Selle⁵; D. Berton-Rigaud⁶; S. Frank⁷; T. De La Motte Rouge⁸; E. Kalbacher⁹; M. Provansal Gross¹⁰; A. Lortholary¹¹; H. Orfeuvre¹²; J. Alexandre¹³; P. Augereau¹⁴; C. Nadeau¹⁵; J.E. Kurtz¹⁶; J.-M. Grellard²; P. Pautier¹⁷; F. Gernier², ¹Centre François Baclesse, Caen, France, ²Centre Francois Baclesse, Caen, Cedex, France, ³Centre Léon Bérard, Lyon, France, ⁴Institute Bergonié, Bordeaux, France, ⁵Groupe Hospitalier Diaconesses Croix Saint Simon, Paris, France, ⁶ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, France, ⁷Institut Curie, Paris, France, ⁸Centre Eugene - Marquis, Rennes, France, ⁹CHRU Besancon - Hopital Jean Minjoz, Besancon, France, ¹⁰Institute Paoli Calmettes, Marseille, France, ¹¹Centre Catherine de Sienne, Nantes, France, ¹²Ch Fleyriat, Bourg En Bresse, France, ¹³Hopital Cochin - Site Port-Royal AP-HP, Paris, France, ¹⁴Centre Paul Papin, Angers, France, ¹⁵CHU Poitiers - Jean Bernard Hôpital, Poitiers, France, ¹⁶ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, France, ¹⁷Institut Gustave Roussy, Villejuif, Cedex, France
- 12:10 - 12:10 **20P - A single-center retrospective analysis of clinical patterns, management and survival outcomes of malignant ovarian germ cell tumors**
Ghazal Tansir¹; S. Khurana¹; P. Malik²; R. Pramanik²; L. Kumar¹; N. Bhatla¹, ¹AIIMS - All India Institute of Medical Sciences, New Delhi, India, ²Institute Rotary Cancer Hospital, New Delhi, India
- 12:10 - 12:10 **21P - Medullary carcinoma of the breast: About 18 cases**
Ons Bettaieb¹; H. Chahdoura²; H. Haj Abdallah³; F. Bouguerra⁴; N. Bouzid¹; S. Kanoun Belajouza¹; S. Tebra⁵, ¹CHU Farhat Hached Sousse, Sousse, Tunisia, ²CHU Farhat Hached Sousse, Sousse, Tunisia, ³University of Sousse - Faculty of medicine, Sousse, Tunisia, ⁴ISA - Institut Salah Azaiez, Tunis, Tunisia, ⁵CHU Farhat Hached, Sousse, Tunisia
- 12:10 - 12:10 **Head and neck cancers**
- 12:10 - 12:10 **23P - Treatment outcomes in nasal cavity and paranasal sinus tumors treated with postoperative volumetric modulated arc therapy**
Amit Bahl¹; N. Panda²; J. Bakshi²; R. Verma²; A.S. Oinam¹; S. Mohindra²; S. Ghoshal¹; R. Gupta², ¹PGIMER - Postgraduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India, ²PGIMER - Post Graduate Institute of Medical Education and Research, Chandigarh, India



- 12:10 - 12:10 **24P - TPD54 as a candidate biomarker for distant metastasis prediction in non-endemic nasopharyngeal carcinoma: Label-free quantitative proteomics results**
Eduardo Netto¹; H. Santos²; L. Carvalho²; S. Esteves³; F. Silva⁴; M. Rito¹; J. Cabeçadas¹,
¹Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa), Lisbon, Portugal, ²BIOSCOPE Research Group, LAQV-REQUIMTE, Chemistry Department, NOVA School of Science and Technology, FCT NOVA, Universidade NOVA de Lisboa, Caparica, Portugal, ³Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa), Lisbon, Portugal, ⁴NOVA Medical School - Faculdade de Ciências Médicas, Lisbon, Portugal
- 12:10 - 12:10 **25P - RC48-ADC for metastatic salivary duct carcinoma with HER2-expression: A single-center retrospective study**
Jun Cao; Q. Ji, Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang Cancer Hospital, Hangzhou, China
- 12:10 - 12:10 **26P - Characterization of a unique immortal tumor cell line as preclinical model for sinonasal teratocarcinoma**
Mario Hermsen, Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain
- 12:10 - 12:10 **Neuroendocrine and Endocrine cancers**
- 12:10 - 12:10 **30P - Bone fragility in patients with adrenocortical carcinoma undergoing mitotane therapy**
D. Cosentini¹; S. Grisanti¹; Marta Laganà¹; N. Di Meo²; V. Cremaschi¹; A. Turla¹; C. Cappelli³; P. Loli⁴; D. Farina²; A. Berruti¹, ¹Medical Oncology Unit, Brescia, Italy, ²Radiology 2, Brescia, Italy, ³Unit of Endocrinology and Metabolism, Brescia, Italy, ⁴Unit of Endocrinology, Milan, Italy
- 12:10 - 12:10 **31P - Bone metastases and skeletal related events in pheochromocytoma and paraganglioma patients: International, retrospective study**
Marta Laganà¹; D. Cosentini²; S. Grisanti³; H. Remde⁴; M. Almeida⁵; S. Pusceddu⁶; T. Deutschbein⁷; G. Fagundes⁵; A. Pereira⁵; C. Grana⁸; N. Fazio⁹; E. Corssmit¹⁰; A. Bongiovanni¹¹; L. Canu¹²; E. Kim¹³; M. Habra¹⁴; C. Jimenez¹⁵; A. Berruti², ¹Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy, ²Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy, ³University of Brescia, Brescia, Italy, ⁴university of wurzburg, wurzburg, Germany, ⁵University of Sao Paulo Medical School, san paulo, Brazil, ⁶Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy, ⁷University Hospital Würzburg, Würzburg, Germany, ⁸IEO - Istituto Europeo di Oncologia, Milan, Italy, ⁹IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy, ¹⁰LUMC-Leiden University Medical Center, Leiden, Netherlands, ¹¹IRST - Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS S.r.l., Meldola, Italy, ¹²Azienda Ospedaliera Careggi, Firenze, Italy, ¹³St Bartholomew's Hospital, London; William Harvey Research Institute, Queen Mary University of London,, london, United Kingdom, ¹⁴The University of Texas M. D. Anderson Cancer Center, Houston, United States of America, ¹⁵Banner MD Anderson Cancer Center, Gilbert, United States of America



- 12:10 - 12:10 **32P - The result of radiotherapy (RT) in patients with parathyroid carcinoma (PC): Experience of National Research Institute of Oncology in Poland, Gliwice Branch (NRIO)**
Marzena Gawkowska¹; B. Michalik²; B. Jurecka-Lubieniecka²; A. Cortez³; Z. Kolosza³,
¹Maria Skłodowska-Curie National Research Institute, National Institute of Oncology, Gliwice, Poland, ²Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice, Poland, ³Maria Skłodowska-Curie Institute - Oncology Center (MSCI), Gliwice Branch, Gliwice, Poland
- 12:10 - 12:10 **33P - Pheochromocytoma during pregnancy in Sweden from 1973-2015: Short and long-term outcome**
Lisa Gunnesson¹; O. Ragnarsson²; M. Nilsson¹; V. Sengpiel²; A. Muth¹, ¹Sahlgrenska University Hospital, Göteborg, Sweden, ²Sahlgrenska University Hospital, Gothenburg, Sweden
- 12:10 - 12:10 **34P - Genomic profiling of NEN patients: Prognostic and therapeutic relevance**
Beatriz Antón Pascual¹; A. Modrego²; A. La Salvia³; A. Lens-Pardo⁴; C. Carretero-Puche⁵; B. Rubio-Cuesta⁵; B. Soldevilla¹; A. Teijo¹; R. Garcia-Carbonero⁶, ¹Hospital 12 de Octubre, Madrid, Spain, ²Hospital Universitario 12 de Octubre, Madrid, Spain, ³IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, Italy, ⁴UCM - Universidad Complutense de Madrid, Madrid, Spain, ⁵Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12) and CNIO, Madrid, Spain, ⁶Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CNIO, Hospital Universitario Doce de Octubre. Universidad Complutense de Madrid, Madrid, Spain
- 12:10 - 12:10 **35P - Feasibility and activity of megestrol acetate in addition to EDP-M as first-line therapy in patients with metastatic/unresectable adrenocortical carcinoma**
Antonella Turla¹; M. Laganà¹; D. Cosentini¹; M. Zamparini¹; R. Ambrosini²; V. Cremaschi¹; G. Tiberio³; A. Abate⁴; M. Tamburello⁴; S. Sigala⁴; S. Grisanti¹; A. Berruti¹,
¹Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy, ²ASST Spedali Civili, Brescia, Italy, ³Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy, ⁴University of Brescia, Brescia, Italy
- 12:10 - 12:10 **36P - Response to peptide receptor radionuclide therapy in pheochromocytomas and paragangliomas: A systematic review and meta-analysis**
Antonella Lucia Marretta, Azienda Ospedaliera Universitaria Federico II, Napoli, Italy
- 12:10 - 12:10 **37P - Survival and prognostic factors in appendiceal neuroendocrine tumours and goblet cell carcinoma**
Kim Dijke, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Amsterdam, Netherlands
- 12:10 - 12:10 **39P - Neuroendocrine neoplasms: A retrospective analysis in a single Algerian institution**
Djihed Belabdi¹; M. Oukkal², ¹CHU Beni-Messous, Alger, Algeria, ²CHU Isaad Hassani de



Beni Messous, Algiers, Algeria

- 12:10 - 12:10 **40TiP - Activity of the addition of progesterone to standard EDP-M scheme in patients with advanced adrenocortical carcinoma: A randomized, placebo-controlled phase II trial (PESETA)**
Valentina Cremaschi¹; D. Cosentini¹; A. Abate²; M. Boglioni¹; M. Laganà¹; M. Tamburello²; R. Ambrosini³; F. Dondi⁴; M. Giacchè⁵; G. Tiberio⁶; S. Grisanti¹; S. Sigala²; A. Berruti¹, ¹Medical Oncology Unit, Brescia, Italy, ²University of Brescia, Brescia, Italy, ³ASST Spedali Civili, Brescia, Italy, ⁴Nuclear Medicine Unit, Brescia, Italy, ⁵Internal Medicine Unit, Brescia, Italy, ⁶Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy
- 12:10 - 12:10 **Public Policy and Patient Advocacy**
- 12:10 - 12:10 **41P - Addressing the unmet need for salivary gland cancers in the UK and beyond**
Emma Kinloch¹; R. Metcalf², ¹Salivary Gland Cancer UK, London, United Kingdom, ²The Christie NHS Foundation Trust, Manchester, United Kingdom
- 12:10 - 12:10 **Sarcoma**
- 12:10 - 12:10 **100P - Combinatorial treatment strategies for overcoming the immunotherapy resistance in soft tissue sarcomas**
Zuzana Strizova¹; A. Ozaniak², ¹University Hospital Motol, Charles University, Prague, Czech Republic, ²University Hospital Motol, Charles University, Praha, Czech Republic
- 12:10 - 12:10 **101P - Pharmacological inhibition of glyoxalase-1 as novel therapeutic strategy to enhance trabectedin anti-tumor effect in soft tissue sarcoma preclinical models**
Bruno Vincenzi¹; S. Simonetti²; M. Iuliani²; S. Cavaliere²; A. Napolitano³; D. Santini⁴; G. Tonini¹; M.J. Guillén⁵; P. Avilés⁵; F. Pantano¹, ¹Policlinico Universitario Campus Bio-Medico, Rome, Italy, ²UCBM - Università Campus Bio-Medico di Roma, Rome, Italy, ³The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, United Kingdom, ⁴Università degli Studi di Roma la Sapienza - Facoltà di Medicina, Latina, Italy, ⁵PharmaMar S.A., Colmenar Viejo, Spain
- 12:10 - 12:10 **102P - Transcriptomic and enhancer landscape profiling identify Src-family kinase LYN as a candidate therapeutic target in human angiosarcoma**
Jason Yongsheng Chan¹; P. Guan²; J.H. Hong³; E.C.Y. Lee¹; J.Y. Lee¹; T.K. Ko¹; B.T. Teh¹, ¹NCCS - National Cancer Centre Singapore, Singapore, Singapore, ²A*STAR - Genome Institute of Singapore (GIS), Singapore, Singapore, ³NUS - National University of Singapore, Singapore, Singapore
- 12:10 - 12:10 **103P - Analysis of resected liposarcoma tumors identifies CD73 as a potential therapeutic target**



Jacqueline Oliva Ramirez¹; Y. Lee¹; R. Rodriguez²; K. Tomczak¹; X. Zhou¹; V. Ravi³; A. Conley⁴; D. Ingram¹; J. Livingston¹; J. Ludwing⁵; N. Somaiah⁴; C. Haymaker⁴, ¹MD Anderson Cancer Center, Houston, United States of America, ²Wellesley College, Wellesley, United States of America, ³The University of Texas MD Anderson Cancer Center - Main Building, Houston, United States of America, ⁴The University of Texas M. D. Anderson Cancer Center, Houston, United States of America, ⁵The University of Texas MD Anderson Cancer Center, Houston, United States of America

12:10 - 12:10 **104P - Multi-omic profiling and real-time ex vivo modelling of imatinib-resistant dermatofibrosarcoma protuberans with fibrosarcomatous transformation**

Jason Yongsheng Chan; E.C.Y. Lee; Z. Li; J.Y. Lee; A.H. Lim; E. Poon, NCCS - National Cancer Centre Singapore, Singapore, Singapore

12:10 - 12:10 **105P - SFX-01 in the treatment of rhabdomyosarcoma: Preclinical results in cellular models**

Simona Camero¹; L. Milazzo²; F. Vulcano²; F. Pedini²; P. Pontecorvi³; G. Gerini³; S. Ceccarelli³; E. Anastasiadou³; S. Pomella⁴; M. Cassandri⁴; A. Porrazzo⁴; R. Rota⁴; C. Marchese³; F. Midulla¹; F. Marampon³; F. Megiorni³, ¹Sapienza University of Rome, Rome, Italy, ²Istituto Superiore di Sanità (ISS), Rome, Italy, ³Sapienza - Università di Roma, Rome, Italy, ⁴Ospedale Pediatrico Bambino Gesù, Rome, Italy

12:10 - 12:10 **106P - Synergistic effect of CDK4/6 inhibitors and standard chemotherapy sequential treatment on liposarcoma patient-derived primary culture**

Silvia Vanni¹; G. Gallo²; V. Fausti¹; G. Miserocchi¹; C. Liverani¹; C. Spadazzi¹; C. Cocchi¹; C. Calabrese¹; S. Gabellone¹; G. De Luca²; M. Bassi²; M. Gessaroli²; A. Campobassi²; F. Pieri³; G. Ercolani³; D. Cavaliere³; L. Gurrieri¹; M. Riva¹; L. Mercatali¹; A. De Vita¹, ¹IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy, ²Bufalini Hospital, Cesena, Italy, ³Morgagni-Pierantoni Hospital, Forlì, Italy

12:10 - 12:10 **107P - The actin cytoskeleton as a new target structure for metastasizing osteosarcoma**

Christina Schreck; E. Schönhals; A. Loersch; F. Bassermann; R. Oostendorp; J. Hecker, Klinikum Rechts der Isar - Technische Universität München, Munich, Germany

12:10 - 12:10 **108P - New biomarkers in liposarcomas: A metabolic approach**

Alix Bouillin¹; L. Gayte²; N. Firmin³; S. Carrere¹; L. Linares², ¹ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, France, ²Institut de recherche en cancérologie de Montpellier, Montpellier, France, ³Icm Val D Aurelle, Montpellier, France

12:10 - 12:10 **109P - Unraveling homologous recombination deficiency and therapeutic opportunities in soft tissue and bone sarcoma**

Lara Planas-Paz¹; A. Pliego-Mendieta²; C. Hagedorn²; D. Aguilera Garcia³; M. Haberecker⁴; F. Arnold⁵; M. Herzog²; L. Bankel⁶; R. Guggenberger⁷; S. Steiner¹; Y. Chen²; A. Kahraman⁸; M. Zoche²; M. Rubin⁹; H. Moch³; C. Britschgi⁶; C. Pauli¹⁰, ¹University Hospital Zürich, Zurich, Switzerland, ²USZ - Institut für Pathologie und Molekularpathologie, Zurich, Switzerland, ³University Hospital Zurich - Institute of Neuropathology, Zurich, Switzerland, ⁴USZ - University Hospital Zurich - Institute of



Pathology, Zurich, Switzerland, ⁵University Hospital Zurich, Zurich, Switzerland, ⁶USZ - University Hospital Zürich, Zurich, Switzerland, ⁷USZ - University Hospital Zurich - Institut für Diagnostische und Interventionelle Radiologie, Zurich, Switzerland, ⁸Hochschule für Life Sciences FHNW - Institut für Medizintechnik und Medizininformatik, Muttenz, Switzerland, ⁹University of Bern - DBMR, Bern, Switzerland, ¹⁰USZ - University Hospital Zurich - Institute of Neuropathology, Zurich, Switzerland

- 12:10 - 12:10 **110P - Characterization of miRNA-mRNA network in soft tissue sarcoma**
Serena Pillozzi¹; F. Scolari²; G. Scoccianti²; A. Boddi³; I. Palchetti³; L. Antonuzzo²; D.A. Campanacci², ¹University of Florence, Florence, Italy, ²AOUC - Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy, ³University of Florence, Firenze, Italy
- 12:10 - 12:10 **111P - A novel immune cell signature for predicting pleomorphic sarcoma prognosis**
Elisabetta Gambale¹; F. Scolari²; G. Scoccianti²; E. Caliman²; A. Palomba²; L. Antonuzzo²; D.A. Campanacci²; S. Pillozzi³, ¹Azienda Ospedaliera Careggi U.O. Oncologia Medica, Firenze, Italy, ²AOUC - Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy, ³University of Florence, Florence, Italy
- 12:10 - 12:10 **112P - (Withdrawn)**
- 12:10 - 12:10 **113P - ANZSA guideline on chemotherapy in primary resectable retroperitoneal sarcoma**
Elizabeth Connolly¹; D. Zhou¹; J. Mar²; S. Lazarakis²; P. Grimison³; J. Connor⁴; A. Hong⁵, ¹Chris O'Brien Lifehouse, Camperdown, Australia, ²Peter MacCallum Cancer Center, Melbourne, Australia, ³Chris O'Brien Lifehouse, Camperdown, Australia, ⁴Auckland City Hospital, Auckland, New Zealand, ⁵Royal Prince Alfred Hospital, Camperdown, Australia
- 12:10 - 12:10 **114TiP - Preliminary assessment of safety and tolerability of dostarlimab in combination antiretroviral therapy (cART)-refractory HIV-associated Kaposi sarcoma (StarKap)**
Claudia Fulgenzi¹; A. Dalla Pria²; M. Bower²; D. Pinato³, ¹Imperial College London, London, United Kingdom, ²Chelsea and Westminster Hospital - NHS Trust, London, United Kingdom, ³Imperial College London - Hammersmith Hospital, London, United Kingdom
- 12:10 - 12:10 **115TiP - MYTH Study: Methotrexate for AYA in the home: A study of safety, feasibility, patient acceptability and cost effectiveness of an ambulatory model for AYA osteosarcoma patients**
Elizabeth Connolly¹; K. Thomson¹; D. King¹; K. Schilling¹; J. Ryan²; P. Grimison¹; D. Zhou¹; B. Zhang¹; M. Strach¹; A. Baker²; T. Sibbald²; V. Bhadri¹, ¹Chris O'Brien Lifehouse, Sydney, Australia, ²The Children's Hospital at Westmead, Westmead, Australia
- 12:10 - 12:10 **116TiP - A phase I/II study of mecbotamab vedotin (BA3011), a CAB-AXL-ADC, in patients with advanced sarcoma including undifferentiated pleomorphic sarcoma**



Breelyn Wilky¹; J. Rodon²; M. Ingham³; S. Pollack⁴; A. Conley², ¹UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, United States of America, ²The University of Texas M. D. Anderson Cancer Center, Houston, United States of America, ³Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, United States of America, ⁴Northwestern University Feinberg School of Medicine, Chicago, United States of America

12:10 - 12:10 **51P - Outcomes of adult patients undergoing extrapleural pneumonectomy for sarcoma at a specialised centre**

Betty Zhang¹; A. Wilson-Smith²; N. Ussher²; E. Connolly³; M. Strach¹; V. Bhadri¹, ¹Chris O'Brien Lifehouse, Camperdown, Australia, ²University of Sydney, Sydney, Australia, ³Chris O'Brien Lifehouse, Camperdown, Australia

12:10 - 12:10 **52P - Long-term outcomes in children, adolescents, and young adults with localized Ewing sarcoma treated with standard vs dose-intensified ifosfamide**

Michael Kinnaman¹; C. Goodboy²; V. Avutu³; J. Glade Bender¹; M. Dickson³; F. Dela Cruz¹; T. O'Donohue¹; W.D. Tap³; L. Wexler¹; E. Slotkin¹; E.A. Kolb⁴; B. Kushner¹; P. Meyers¹, ¹Memorial Sloan Kettering Cancer Center, New York, United States of America, ²Children's Hospital of Philadelphia, Philadelphia, United States of America, ³MSKCC - Memorial Sloan Kettering Cancer Center, New York, United States of America, ⁴Nemours Alfred I. duPont Hospital for Children, Wilmington, United States of America

12:10 - 12:10 **53P - Oral metronomic-continuous cyclophosphamide (MCy) for elderly or unfit patients with advanced soft tissue sarcoma (STS): Reina Sofía University Hospital experience**

Alberto Luis Moreno Vega; L. Navarro Berlanga; R. Plaza Borrego; M.T. Caro Cuenca; M.A. Gomez Espa&#ntilde;a; E. Aranda Aguilar, Hospital Universitario Reina Sof&#ntilde;a, Cordoba, Spain

12:10 - 12:10 **54P - Evaluation with FDG-PET during pretreatment of gastrointestinal stromal tumour, GIST, with imatinib**

Stefan Lindskog¹; E. Hancke¹; M. Berndsen², ¹Sahlgrenska University Hospital, Sahlgrenska Academy, Göteborg, Sweden, ²Sahlgrenska University Hospital, Göteborg, Sweden

12:10 - 12:10 **55P - Our experience of the hormone therapy in uterine sarcoma patients**

Viktoriia Kovalchuk¹; M. Krasnoselskiy²; V. Sukhin³; O. Mihanovskiy²; O. Sukhina³; H. Hranovska⁴; A. Nasonova³; K. Nemaltsova²; S. Danilyuk²; O. Dolhaia², ¹Grigoriev Institute for Medical Radiology and Oncology NAMS of Ukraine, Kharkiv, KHARKIV, Ukraine, ²Institute of Medical Radiology of S. P. Grigoriev National Academy of Medical Sciences of Ukraine, Kharkiv, Ukraine, ³State Institute for Medical Radiology AMSU, Kharkiv, Ukraine, ⁴Grigoriev Institute for Medical Radiology and Oncology NAMS of Ukraine, Kharkiv, Kharkiv, Ukraine

12:10 - 12:10 **56P - Pembrolizumab in advanced mesenchymal tumors: A prospective monocentric study**

Malvina Cremante; F. Catalano; D. Comandini; M. Mascherini; F. Zaottini; R. Picasso; B.



Spina; A. Guadagno; M. Grassi, IRCCS Ospedale Policlinico San Martino, Genova, Italy

- 12:10 - 12:10 **57P - Two cases of adult rhabdomyosarcoma of the head and neck successfully treated with pazopanib**
Yoshihiro Okita¹; H. Okuyama¹; A. Murakami¹; K. Nomura²; I. Kita¹; S. Tsukamoto³; T. Nishiuchi²; A. Tsuji¹, ¹Kagawa University Faculty of Medicine/Graduate School of Medicine, Miki, Japan, ²Takamatsu Red Cross Hospital, Takamatsu, Japan, ³Kagawa University, Miki-cho, Japan
- 12:10 - 12:10 **58P - Evaluating the impact of WGTS in routine diagnostics of bone and soft tissue tumors**
Karin Wallander; I. Öfverholm; L. Yingbo; C. Haglund; V. Chellappa; P. Tsagkozis; A. Hesla; A. Papakonstantinou; R. Bränström; V. Wirta; J. Lindberg; F. Haglund De Flon, Karolinska Institutet, Solna, Sweden
- 12:10 - 12:10 **59P - Introducing liquid biopsy for paediatric sarcoma patients into the clinical routine**
Andreas Leithner¹; M.G. Seidel¹; T. Moser¹; A. Thueringer²; B. Liegl-Atzwanger¹; J. Szkandera¹; M. Benesch¹; A. El-Heliebi¹; E. Heitzer¹; K. Kashofer¹, ¹Medical University of Graz, Graz, Austria, ²Medical University of Graz - Institute of Pathology, Graz, Austria
- 12:10 - 12:10 **60P - The diagnostic pathway of sarcoma patients: Results from the QUEST study in the Netherlands and the United Kingdom: A cohort study**
Emily Holthuis¹; V. Soomers²; W. Van Houdt³; J. Van Der Hage⁴; L. Been⁵; H. Bonenkamp²; K. Verhoef⁶; A. Hayes⁷; R. Young⁸; R. Jones⁹; M. Leahy¹⁰; M. Parry¹¹; W. Van Der Graaf³; O. Husson³, ¹Erasmus MC, Rotterdam, Netherlands, ²Radboud University Medical Center, Nijmegen, Netherlands, ³NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands, ⁴LUMC - Universitair Medisch Centrum, Leiden, Netherlands, ⁵UMCG - University Medical Center Groningen, Groningen, Netherlands, ⁶Erasmus MC - University Medical Center, Rotterdam, Netherlands, ⁷The Royal Marsden Hospital - NHS Foundation Trust, London, United Kingdom, ⁸Weston Park Hospital - Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom, ⁹The Royal Marsden Hospital - Chelsea, London, United Kingdom, ¹⁰The Christie NHS Foundation Trust, Manchester, United Kingdom, ¹¹Royal Orthopaedic Hospital - NHS Foundation Trust, Birmingham, United Kingdom
- 12:10 - 12:10 **61P - Pazopanib in the real-world setting: Data from the Italian national registry**
Alessandro Mazzocca¹; B. Vincenzi¹; A. Comandone²; S. Celant³; P.P. Olimpieri³; S. Di Segni³; P. Russo³; P.G. Casali⁴, ¹Policlinico Universitario Campus Bio-Medico, Rome, Italy, ²Ospedale San Giovanni Bosco, Torino, Italy, ³AIFA - Agenzia Italiana del Farmaco, Rome, Italy, ⁴Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy
- 12:10 - 12:10 **62P - Digital narrative diary: The role in daily clinical practice of soft tissue and bone sarcomas patients**
Dorelsa Buccilli¹; C.E. Onesti²; S. Vari²; G. Maggi²; W. Faltyn²; C. Cenci³; S. Ceddia²; R. Biagini²; V. Ferraresi²; M.C. Cercato⁴, ¹UOSD Sarcomas and Rare Tumors, IRCCS Regina Elena National Cancer Institute (IRE), Rome, Italy, ²IRCCS Regina Elena National Cancer Institute (IRE), Rome, Italy, ³(DNM s.r.l.), Roma, Italy, ⁴IRCCS Istituto Nazionale Tumori



Regina Elena (IRE), Rome, Italy

- 12:10 - 12:10 **63P - Gastrointestinal stromal tumours in the imatinib era: Outcomes of a treatment and follow-up programme in Western Sweden from 2004-2020**
Marta Berndsen¹; F. Puls²; A. Muth¹; S. Lindskog², ¹Gothenburg University, Göteborg, Sweden, ²Sahlgrenska University Hospital, Göteborg, Sweden
- 12:10 - 12:10 **64P - Tertiary lymphoid structure and efficacy of doxorubicin in patients with soft tissue sarcoma: The Centre Léon Bérard experience**
Massimiliano Grassi¹; A. Dufresne²; M. Karanian²; A. Meurgey²; A. Bouhamama²; M.-P. Sunyach³; P. Meeus²; F. Gouin²; G. Vaz²; I. Ray-Coquard²; J.-Y. Blay²; M. Brahmi², ¹IRCCS Ospedale Policlinico San Martino, Genova, Italy, ²Centre Léon Bérard, Lyon, France, ³Center Leon Berard, Lyon, France
- 12:10 - 12:10 **65P - Continued improvement in overall survival from extremity soft tissue sarcoma over 28 years**
Mohyeddine El Sayed¹; R. Zastrow²; A. Levin², ¹AUBMC - American University of Beirut Medical Center, Beirut, Lebanon, ²Johns Hopkins Hospital, Baltimore, United States of America
- 12:10 - 12:10 **66P - Therapeutic opportunities in sarcomas and rare tumors: What path for antibody-drug conjugates?**
Helene Vanacker¹; M. Brahmi¹; P. Cassier¹; D. Pissaloux¹; S. Boyault¹; F. Tirode²; J.-Y. Blay¹; A. Dufresne¹, ¹Centre Léon Bérard, Lyon, France, ²Inserm, Lyon, France
- 12:10 - 12:10 **67P - Detrimental effect of the COVID-19 pandemic on patients with adult extremity bone sarcoma: Reference center experience**
Pawel Teterycz; B. Szostakowski; M. Rosinska; H. Kosela Paterczyk; P. Rutkowski, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
- 12:10 - 12:10 **68P - Optimization of giant cell tumor treatment: First Russian big data**
Anastasia Tararykova¹; A. Fedenko²; E. Musaev³, ¹National Medical Research Center of Oncology named after N.N. Blokhin, Moscow, Russian Federation, ²P.A. Herzen Moscow Cancer Research Center, Moscow, Russian Federation, ³Moscow Oncological Hospital 62 of the Moscow Department of Health, Moskovskaya oblast, Russian Federation
- 12:10 - 12:10 **69P - Trabectedin rechallenge for the treatment of adults with advanced soft tissue sarcoma (STS): A pilot study (Re-Trabe)**
Giuseppe Badalamenti; L. Algeri; A. Dimino; L. Magrin; I. De Luca; R. Sciacchitano; F. Alimondi; V. Gennusa; I. Caiozzo; T.D. Bazan Russo; A. Galvano; V. Gristina; V. Bazan; L. Incorvaia; A. Russo, University of Palermo, Palermo, Italy
- 12:10 - 12:10 **70P - Total neoadjuvant vs standard perioperative cisplatin/doxorubicin chemotherapy in patients with extremities osteosarcoma: A single-center cohort study**
Seyed Alireza Javadinia¹; A.M. Arefpour²; A. Nikoofar³; M. Sanei²; S.H. Mahdavi²; A. Foroughi², ¹Sabzevar University of Medical Sciences, Sabzevar, Iran, ²Iran University of



Medical Sciences, Tehran, Iran, ³Pars Hospital, Tehran, Iran

- 12:10 - 12:10 **71P - Does age impact outcomes of osteosarcoma? A single-center retrospective evaluation of the demographic profile and outcome of osteosarcoma in patients more than 40 years of age**
Prabhat Bhargava; S. Srinivas; R. Shenoy; D. Shah; A. Gulia; M. Prurthi; P. Nayak; A. Janu; N. Chakrabarty; N. Purandare; M. Ramadwar; B. Rekhi; P. Panjwani; A. Puri; J. Bajpai, Tata Memorial Hospital - Tata Memorial Centre, Mumbai, India
- 12:10 - 12:10 **72P - Molecular characterization of advanced primary cardiac sarcomas**
Alberto Giuseppe Agostara¹; G. Patelli¹; K. Bencardino²; C. Lauricella²; S. Pierri¹; G. Ciarlo¹; G. Calvanese¹; V. Gori¹; S. Mariano²; T. Cipani²; F. Settepani²; F. Soriano²; A. Moreo²; F. Navarra³; M. Mascarini³; V. Caputo²; S. Veronese²; C.F. Russo²; A. Sartore Bianchi¹; S. Siena¹, ¹Università degli Studi di Milano Statale, Milan, Italy, ²ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ³CRO Centro di Riferimento Oncologico IRCCS, Aviano, Italy
- 12:10 - 12:10 **73P - Proton radiotherapy in treatment of desmoid tumors**
Michaela Lipanova¹; J. Kubes²; K. Kopeckova¹; P. Pacas¹; T. Buchler¹, ¹Motol University Hospital, Prague, Czech Republic, ²Proton Therapy Center Czech, Prague, Czech Republic
- 12:10 - 12:10 **75P - Primary sarcomas of gastrointestinal tract: A single-institution experience of a rare entity**
Divya Khosla; R. Kapoor; V. Kataria; A. Sekar; C. Das; D. Kumar; R. Gupta; V. Gupta; H. Singh; T. Dey; R. Madan; R. Nada, PGIMER - Postgraduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India
- 12:10 - 12:10 **76P - Thoracic synovial sarcoma: A single-center, real-world analysis of treatment paradigms and clinical outcomes**
Ghazal Tansir¹; S. Rastogi²; S. Fernandes³; S. Ahmed Shamim³; E. Dhamija³; A. Barwad³; R. Pandey³, ¹AIIMS - All India Institute of Medical Sciences, Noida, India, ²All India Institute of Medical Sciences, New Delhi, India, ³AIIMS - All India Institute of Medical Sciences, New Delhi, India
- 12:10 - 12:10 **77P - 5-year results of cytoreductive surgery in peritoneal and retroperitoneal sarcomatosis**
Pirilti Ozcan¹; Ö. Düzgün², ¹Istanbul University - Cerrahpasa Faculty of Medicine, Istanbul, Turkey, ²University of Health Sciences, Istanbul, Turkey
- 12:10 - 12:10 **78P - Dose-dense epirubicin and cisplatin (ddEP) in localised osteosarcoma**
Zachariah Thomas; J. Georgy; D.B. Thumaty; A. John; A. Joel; J.P. Wisely; P. Jambunathan; P. Kumar M; H. Kovilapu; R.T. Chacko; P. Madhurima; A. Prabhu; B. Shreemal; M. Kandagaddala; R. Balakrishnan; A. Singh, CMC - Christian Medical College Hospital, Vellore, India
- 12:10 - 12:10 **79P - Ifosfamide neurotoxicity in sarcoma patients: A real-life analysis from a sarcoma referral centre**



Antonella Chiavassa¹; F. Riva¹; S. Vari²; C.E. Onesti²; S. Ceddia²; M. Veroli¹; F. Salvatori¹; G. Maggi³; A. Torchia¹; F. Sperati⁴; V. Ferraresi², ¹Sapienza Università di Roma, Rome, Italy, ²IRCCS Regina Elena National Cancer Institute, Rome, Italy, ³IRCCS Regina Elena National Cancer Institute (IRE), Rome, Italy, ⁴IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, Italy

12:10 - 12:10 **80P - Expanded access program use of ripretinib in advanced GIST patients in the United Kingdom**

Andrea Napolitano¹; S.Y. Lim¹; L. Ferro Lopez²; C. Benson¹; R. Jones¹, ¹The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, United Kingdom, ²The Royal Marsden Hospital - Chelsea, London, United Kingdom

12:10 - 12:10 **81P - Soft tissue solitary fibrous tumor: Analysis of a single center series with a comparison between three prognostic scores**

Guido Scozzianti; A. Palomba; C. Caporalini; F. Nozzoli; R. Scanferla; F. Scolari; S. Pillozzi; D.A. Campanacci, AOUC - Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy

12:10 - 12:10 **82P - Clinical impact of systematic next generation sequencing in bone and soft-tissue sarcomas: Experience of a Spanish reference center**

Marta Arregui Valles¹; C. López Jiménez¹; A. Gutierrez Ortiz¹; N. Gutierrez Alonso²; D. Juliao Caamaño¹; J. Soto Alsar²; M. Bringas Beranek²; M.D.M. Galera López³; R. Alvarez¹, ¹Hospital General Universitario Gregorio Marañon, Madrid, Spain, ²Hospital General Universitario Gregorio Marañon - Fundación Investigación Biomedica, Madrid, Spain, ³Hospital General Universitario Gregorio Marañon, Madrid, Spain

12:10 - 12:10 **83P - Radiological evaluation of response in patients with soft tissue sarcoma treated with trabectedin**

Serena Ceddia¹; S. Vari¹; A. Torchia²; C.E. Onesti¹; A. Cosimati²; M. Veroli²; A. Chiavassa²; F. Riva²; F. Salvatori²; G. Benvenuti²; V. Anelli³; I. Sperduti³; V. Ferraresi¹, ¹IRCCS Regina Elena National Cancer Institute, Rome, Italy, ²Sapienza Università di Roma, Rome, Italy, ³IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, Italy

12:10 - 12:10 **84P - Post-radiation sarcomas: A real-life analysis from a referral centre**

Margherita Veroli¹; S. Vari²; C.E. Onesti²; S. Ceddia²; F. Salvatori¹; A. Chiavassa¹; A. Cosimati¹; A. Torchia¹; F. Riva¹; M.G. Petrongari³; V. Ferraresi², ¹Sapienza - University of Rome, Rome, Italy, ²IRCCS Regina Elena National Cancer Institute, Rome, Italy, ³IRCCS Regina Elena National Cancer Institute (IRE), Rome, Italy

12:10 - 12:10 **85P - Ripretinib dose escalation after disease progression for Chinese patients with advanced gastrointestinal stromal tumor: A multi-center retrospective analysis**

Yongjian Zhou¹; X. Zhang²; X. Sun³; Y. Zhang⁴; K. Mao⁵; H. Liu⁶; N. Liu⁷; Y. Zhou⁸; Y. Meng⁹; B. Tan¹⁰; L. Wang¹¹, ¹Fujian Medical University Union Hospital, Fuzhou, China, ²The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, ³The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China, ⁴Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁵Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, China, ⁶Shandong



Provincial Hospital, Jinan, China, ⁷Tianjin Medical University Cancer Hospital and City Key Laboratory of Tianjin Cancer Center, Tianjin, China, ⁸Fudan University Shanghai Cancer Center, Shanghai, China, ⁹Hainan General Hospital, Haikou, China, ¹⁰The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, ¹¹900 Hospital of the Joint Logistics Support Force of Chinese PLA, Fuzhou, China

- 12:10 - 12:10 **86P - Kaposi's sarcoma: A single-institution experience**
Diana Pessoa¹; M. Neves²; C. Pereira¹; E. Gouveia¹; M.J. Passos¹; P. Pereira¹; H. Nunes¹,
¹Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa), Lisbon, Portugal, ²Centro Hospitalar de Lisboa Ocidental E.P.E. (CHLO)-Hospital São Francisco Xavier (HSFX), Lisbon, Portugal
- 12:10 - 12:10 **87P - Rhabdomyosarcoma in adult patients: Management in a high-volume Spanish sarcoma center**
Rafael Buezas¹; I. Carrasco Garcia²; G. Martínez Bernal²; P. Macias Rodriguez²; P. Sancho Marquez²; J. Benedetti Pedroza², ¹IBIS - Instituto de Biomedicina de Sevilla - Campus Hospital Universitario Virgen del Rocío, Seville, Spain, ²Hospital Universitario Virgen del Rocio, Seville, Spain
- 12:10 - 12:10 **88P - Primary malignant bone sarcomas: Experience of a Portuguese referral center**
R. Ranchor; Manuel Magalhaes; E. Rosendo; A.M. Araújo, Centro Hospitalar Universitário do Porto, Porto, Portugal
- 12:10 - 12:10 **89P - EWSR1-PATZ1 fusion malignancies with completely different clinic histopathological behaviors**
Yu-Ju Kuo¹; J.-C. Lee²; H.-L. Song¹; T.W.-W. Chen², ¹National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan, ²National Taiwan University Hospital, Taipei City, Taiwan
- 12:10 - 12:10 **90P - Virtual sarcoma disease multidisciplinary team: A jump into the future?**
Francesca Salvatori¹; B. Rossi²; C.E. Onesti²; S. Vari²; S. Ceddia²; E. Checcucci²; A. Cosimati¹; F. Riva¹; D. Renna²; R. Biagini²; V. Ferraresi², ¹Sapienza - Università di Roma, Rome, Italy, ²IRCCS Regina Elena National Cancer Institute (IRE), Rome, Italy
- 12:10 - 12:10 **91P - Management challenges of extremity sarcomas in under-resourced settings: The first survey-based study in Morocco**
Saoussane Kharmoum¹; A. Najdi²; J. Kharmoum³; H. Ait Benali³; S. Arifi⁴; S. Naciri⁵; N. Ismaili⁶; M. Elhfid³; M. Chraybi³; H. Errihani⁷; M. Shimi³, ¹Tangier Oncology Center, Tangier, Maroc, Morocco, ²Abdelmalek Essaadi University - Faculty of Sciences of Tetouan, Tetouan, Morocco, ³Faculty of Medicine and Pharmacy Tangier, Tangier, Morocco, ⁴CHU - University Hospital of Hassan II, Fez, Morocco, ⁵Institut National d'Oncologie Sidi Mohamed Ben Abdellah, Rabat, Morocco, ⁶Hôpital Cheikh Khalifa Bin Zayed Al, Casablanca, Morocco, ⁷National institut of oncology, Rabat, Morocco
- 12:10 - 12:10 **93P - Reduced malignancy of super methotrexate-resistant osteosarcoma cells is linked to elevated expression of PI3K/AKT/mTOR and c-MYC**



Yusuke Aoki¹; Y. Tome¹; H. Oshiro¹; K. Mizuta¹; R. Katsuki¹; K. Nishida¹; R. Hoffman²,
¹Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan, ²AntiCancer Inc., San Diego, United States of America

- 12:10 - 12:10 **94P - Retroperitoneal sarcoma: Impact of adjuvant chemo(radio)therapy on survival outcome compared to the standard surgical resection with no systemic therapy**
Asmaa Ellaithy, Suez Canal University, Ismailia, Egypt
- 12:10 - 12:10 **95P - Cardiac sarcoma: Impact of adjuvant chemotherapy versus adjuvant radiotherapy on survival outcome**
Ahmed Elserry¹; A. Ellaithy², ¹Suez Canal University Hospital, Ismailia, Egypt, ²Suez Canal University, Ismailia, Egypt
- 12:10 - 12:10 **96P - Age-adjusted trends and survival analysis of alveolar soft part sarcoma**
Amr Aly; A. Ellaithy, Suez Canal University Hospital, Ismailia, Egypt
- 12:10 - 12:10 **97P - Modern outcomes with re-irradiation, systemic therapy and surgery for radiotherapy-associated angiosarcoma of the breast**
Wafa Asha¹; Z. Alhilli²; R. Djohan³; G.T. Budd²; E. Fleming-Hall²; K. Yang²; R. Tendulkar²; C. Shah², ¹King Hussein Cancer Center, Amman, Jordan, ²Taussig Cancer Center-Cleveland Clinic, Cleveland, United States of America, ³Cleveland Clinic, Cleveland, United States of America
- 12:10 - 12:10 **98P - Safety and toxicity of mifamurtide treatment in patients with osteosarcoma: A single-center experience**
Michal Manisterski; N. Kolender; D. Levin; Y. Peled; R. Elhasid, Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, Israel
- 12:10 - 12:10 **99P - Fibroblast activation protein alpha (FAP) as theranostic target in solitary fibrous tumor**
Rainer Hamacher¹; K.M. Pabst¹; P.F. Cheung¹; C.E. Heilig²; J. Hülle²; S.-T. Liffers¹; B.M. Schaarschmidt¹; P. Costa¹; L. Kessler¹; J. Falkenhorst¹; H. Glimm³; L. Umutlu¹; M. Schuler¹; D. Hübschmann²; S. Bauer¹; S. Fröhling²; K. Herrmann¹; J. Siveke¹; H.-U. Schildhaus¹; W. Fendler¹, ¹University Hospital Essen, West German Cancer Center, Essen, Germany, ²National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany, ³National Center for Tumor Diseases, Partner site Dresden (NCT), Dresden, Germany
- 12:10 - 12:10 **Skin cancers and Melanomas**
- 12:10 - 12:10 **118P - Influence of tumor immune infiltrate characteristics on survival rates of patients with choroid melanoma**
Iryna Zherka¹; K. Ruksha²; O. Gulenko²; L. Naumenko¹; D. Davidov²; A. Portyanko²,
¹State Institution N. N. Alexandrov National Cancer Centre of Belarus, Lesnoy - Minsk District, Belarus, ²N.N. Alexandrov National Cancer Center of Belarus, Lesnoy - Minsk



District, Belarus

- 12:10 - 12:10 **119P - Long-term safety evaluation of roginolisib (formerly IOA-244), a highly selective phosphoinositide 3-kinase inhibitor delta (PI3K β), in a phase I first-in-human (FIH) study**
Anna Di Giacomo¹; P. Mason²; R. Snijder²; A. Abdul-Ahad²; M. Lahn³; L. Van Der Veen³; T. Hammett³; R. Zorrilla³; C. Pickering³; M. Durini⁴; M. Simonelli⁵; C. Carlo-Stella⁵; A. Santoro⁶; P. Spiliopoulou⁷; T.R.J. Evans⁸; M. Maio¹, ¹AOU Senese - Santa Maria delle Scotte, Siena, Italy, ²BOTH Analytics GmbH, Munich, Germany, ³Onctura SA, Geneva, Switzerland, ⁴Covance, Inc. - Labcorp, Milan, Italy, ⁵Humanitas University, Milan, Italy, ⁶Istituto Clinico Humanitas, Rozzano, Italy, ⁷Princess Margaret Cancer Centre, Toronto, Canada, ⁸University of Glasgow, Glasgow, United Kingdom
- 12:10 - 12:10 **120P - Pigmentation level of uveal melanoma and its development**
Justyna Sopol¹; A. Kozińska¹; M. Szczygieł¹; A. Markiewicz²; B. Romanowska-Dixon²; M. Elas¹, ¹Jagiellonian University - Faculty of Biochemistry, Biophysics and Biotechnology, Krakow, Poland, ²Jagiellonian University Collegium Medicum, Krakow, Poland
- 12:10 - 12:10 **121P - Temozolomide plus cisplatin as first-line treatment for advanced or metastatic mucosal melanoma**
Fernando Aldaco Sarvide¹; H. Millán²; M.G. Cervantes Sanchez³, ¹Centro Medico Nacional 20 de Noviembre ISSSTE, Ciudad de Mexico, Mexico, ²FUCAM, Ciudad de Mexico, Mexico, ³ISSSTE - Centro Médico Nacional 20 de Noviembre, Ciudad de Mexico, Mexico
- 12:10 - 12:10 **122P - Impact of surgical management in improving the quality of life in patients diagnosed with Marjolin's ulcer: A prospective observational study from a tertiary care center in India**
R N Naga Irrinki¹; P. Bhagyashree²; K. Siddhant²; J.R. John²; D. Chatterjee², ¹PGIMER - Postgraduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India, ²PGIMER - Post Graduate Institute of Medical Education and Research, Chandigarh, India
- 12:10 - 12:10 **Thoracic cancers**
- 12:10 - 12:10 **123P - Thymic neoplasms in Bavaria between 2002 and 2016: Has there been progress?**
Miriam Bley¹; T. Bolt¹; J.M. Fertmann¹; D. Kauffmann-Guerrero¹; S. Karrasch¹; J. Kovacs¹; C. Schneider¹; G. Schubert-Fritschle²; L. Sellmer¹; J. Walter¹; A. Tufman¹, ¹LMU Klinikum der Universität München, Munich, Germany, ²Munich Cancer Registry, Munich, Germany
- 12:10 - 12:10 **General interest**
- 12:10 - 12:10 **125P - Sirolimus experience in adult patients with vascular anomalies**



Hasan Yildirim¹; A. Akyildiz¹; A. Turker², ¹Hacettepe University Oncology Hospital, Ankara, Turkey, ²Hacettepe University - Faculty of Medicine, Ankara, Turkey

- 12:10 - 12:10 **126P - Comprehensive efforts to address multifaceted issues of rare cancers and sarcomas in Japan**
- Akira Kawai¹; S. Iwata²; T. Shimoi³; E. Kobayashi⁴; K. Ogura¹; A. Yoshida²; H. Okuma³; Y. Goto³; C. Morizane³; Y. Yoshida¹; Y. Katoh³; Y. Yatabe³; K. Yonemori³; K. Nakamura⁵; T. Nishida⁶; T. Higashi³, ¹NCCCH - National Cancer Center Hospital-Tsukiji Campus, Chuo-ku, Japan, ²National Cancer Center Research Institute - Tsukiji Campus, Chuo-ku, Japan, ³National Cancer Center - Tsukiji Campus, Chuo-ku, Japan, ⁴National Cancer Center - Tsukiji Campus, Tokyo, Japan, ⁵National Cancer Center, Tokyo, Japan, ⁶JCHO Osaka Hospital (formerly Osaka Kosei Nenkin Hospital), Osaka, Japan
- 12:10 - 12:10 **127P - Outcomes of advanced chordoma from dedicated sarcoma medical oncology clinic from a tertiary care center in North India**
- Sameer Rastogi¹; S. Fernandes²; N. Sasi²; D. Kashyap²; G. Tansir²; A. Kumar²; S. Gamangati²; A. Barwad²; S. Ahmed Shamim², ¹All India Institute of Medical Sciences, New Delhi, India, ²AIIMS - All India Institute of Medical Sciences, New Delhi, India
- 12:10 - 12:10 **128P - Impact of an online educational activity on oncologists' knowledge regarding the latest developments in the treatment of uveal melanoma**
- Nabil Dorkhom¹; K. Peters²; P. Nathan³; R. Carvajal⁴, ¹Medscape, Naarden, Netherlands, ²Medscape, London, United Kingdom, ³Mount Vernon Cancer Centre - East and North Herts NHS Trust, Northwood, United Kingdom, ⁴Northwell Health Cancer Institute, New York, United States of America
- 12:10 - 12:10 **129P - Denosumab treatment in adults with metastatic, unresectable or resectable high-risk primary giant cell tumor of bone: Real-life cohort**
- Hasan Yildirim¹; A. Akyildiz¹; D.C. Guven¹; E. Chalabiyev¹; F. Kus¹; S. Aksoy¹; A. Turker², ¹Hacettepe University Oncology Hospital, Ankara, Turkey, ²Hacettepe University - Faculty of Medicine, Ankara, Turkey
- 12:10 - 12:10 **131TiP - Measuring health-related quality of life in solid rare cancer patients: A study protocol**
- Catarina Simões Padilla; W. Van Der Graaf; M. Tesselaar; O. Husson, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
- 12:10 - 12:10 **132TiP - Double-blind placebo-controlled trial of AL102 for treatment of progressing desmoid tumors (DT): The RINGSIDE phase III study design**
- Bernd Kasper¹; R. Jones²; J. Yovell³; G. Gordon⁴; M. Gounder⁵, ¹UMM - Universitaetsklinikum Mannheim, Mannheim, Germany, ²The Royal Marsden Hospital - Chelsea, London, United Kingdom, ³Ayala Pharma, Rehovot, Israel, ⁴Ayala Pharmaceutical, Wilmington, United States of America, ⁵Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, United States of America



12:15 - 13:00 **Type: Young Oncologists session** **Hall B3**
Title: YO Vesalius talk - Developing a career in rare cancers: Pitfalls and opportunities
 Moderation: Elizabeth Connolly, Australia; Pawel Sobczuk, Poland

12:15 - 13:00 **Panellists**
Iwona Lugowska¹; William D. Tap²; Christoph Benedikt Westphalen³, ¹Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland, ²MSKCC - Memorial Sloan Kettering Cancer Center, New York, United States of America, ³LMU Klinikum der Universität München, Munich, Germany

13:15 - 14:15 **Type: Industry Satellite Symposium** **Hall B1**
Title: Deciphera - Lessons from clinical development and clinical practice: Therapeutic strategies in advanced GIST
 Moderation: Sebastian Bauer, Germany

13:15 - 13:17 **Welcome and introduction**
Sebastian Bauer, WTZ - Westdeutsches Tumorzentrum Essen, Essen, Germany

13:17 - 13:32 **Recent insights into imatinib-resistant GIST**
Sebastian Bauer, WTZ - Westdeutsches Tumorzentrum Essen, Essen, Germany

13:32 - 13:47 **Maximise treatment benefit in advanced GIST**
Charlotte Benson, The Royal Marsden Hospital - Chelsea, London, United Kingdom

13:47 - 14:02 **Multimodal approaches to treating progressive disease**
Bruno Vincenzi, Policlinico Universitario Campus Bio-Medico, Rome, Italy

14:02 - 14:15 **Discussion and conclusions**
Sebastian Bauer, WTZ - Westdeutsches Tumorzentrum Essen, Essen, Germany



14:30 - 15:50 **Type: Multidisciplinary session** **Hall A**
Title: Multidisciplinary case discussion of paediatric and AYA sarcomas
Moderation: Rick Haas, Netherlands; A. Paolo Dei Tos, Italy

14:30 - 14:35 **Introduction**

14:35 - 14:55 **Case presentation on MPNST + discussion**
Florence Duffaud, CHU La Timone Adultes, Marseille, France

14:55 - 15:15 **Case presentation on synovial sarcoma + discussion**
Andrew Hayes, Royal Marsden Hospital, London, United Kingdom

15:15 - 15:35 **Case presentation on Ewing sarcoma + discussion**

Sandra Strauss, University College London Hospitals NHS Foundation Trust, London, United Kingdom

15:35 - 15:50 **Q&A and discussion**



14:30 - 15:50 **Type: Educational session** **Hall B1**
Title: Management of adrenal tumours
Moderation: Alfredo Berruti, Italy; Rocio Garcia-Carbonero, Spain

14:30 - 14:35 **Introduction**

14:35 - 14:50 **Differences in surgical management of pheochromocytoma and adrenocortical carcinoma**

Andrea Frilling, Hammersmith Hospital - Imperial College Healthcare NHS Trust, London, United Kingdom

14:50 - 15:05 **Adjuvant therapy in the management of radically resected adrenocortical carcinoma: Who, how and for how long**

Massimo Terzolo, University of Turin, Torino, Italy

15:05 - 15:20 **Management of patients with advanced pheochromocytome/paraganglioma**

Alfredo Berruti, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy

15:20 - 15:35 **Management of patients with advanced adrenocortical carcinoma**

Otilia Kimpel, UKW - University Hospital Würzburg, Würzburg, Germany

15:35 - 15:50 **Q&A and discussion**



14:30 - 15:50	Type: Educational session Title: Health data collection and usage in rare cancers Moderation: Annalisa Trama, Italy; Yiannos Toliás, Belgium	Hall B3
14:30 - 14:35	Introduction: The academia and its data	
14:35 - 14:50	Epidemiological and clinical registries <u>Annalisa Trama</u> , Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy	
14:50 - 15:05	Enabling Large-scale analysis of observational health data <u>Peter Rijnbeek</u> , Erasmus MC, Rotterdam, Netherlands	
15:05 - 15:20	The EU Health Data Space <u>Yiannos Toliás</u> , European Commission, Brussels, Belgium	
15:20 - 15:35	Non-trial data for new drug approval <u>Douwe Postmus</u> , University of Groningen, Groningen, Netherlands	
15:35 - 15:50	Q&A and discussion	
15:50 - 16:20	Type: Coffee break Title: Coffee break	Foyer (Ground floor)



16:20 - 17:40 **Type: Educational session** **Hall A**
Title: Chondrosarcomas
Moderation: A. Paolo Dei Tos, Italy; Sanne Venneker, Netherlands

16:20 - 16:25 **Introduction**

16:25 - 16:40 **Extraskeletal myxoid chondrosarcoma: Chondrosarcoma or misnomer?**
A. Paolo Dei Tos, University of Padua - School of Medicine, Padua, Italy

16:40 - 16:55 **IDH inhibitors in chondrosarcoma**
Jonathan Trent, Sylvester Comprehensive Cancer Center - University of Miami, Miami, United States of America

16:55 - 17:10 **Basic science on IDH in chondrosarcoma: Why have clinical trials been disappointing?**
Sanne Venneker, LUMC-Leiden University Medical Center, Leiden, Netherlands

17:10 - 17:25 **Apoptosis and death receptor inhibition in chondrosarcoma: From preclinical data to clinical trial**
Aurelie Dutour, Centre Léon Bérard, Lyon, France

17:25 - 17:40 **Q&A and discussion**



16:20 - 17:40	Type: Educational session Title: State-of-the-art management of patients with rare tumours of the head neck and thorax Moderation: Solange Peters, Switzerland; Keith Hunter, United Kingdom	Hall B1
16:20 - 16:25	Introduction	
16:25 - 16:40	SCLC-Novel systemic treatment approaches <u>Solange Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland	
16:40 - 16:55	Thymoma: Multidisciplinary therapeutic options <u>Nicolas Girard</u> , Institut Curie, Paris, France	
16:55 - 17:10	Nasopharyngeal cancers: The role of chemotherapy and immunotherapy <u>Brigette Ma</u> , The Chinese University of Hong Kong, Sha Tin, Hong Kong PRC	
17:10 - 17:25	Paranasal cancers: Histology as a treatment driver <u>Keith Hunter</u> , University of Liverpool - School of Medicine, Liverpool, United Kingdom	
17:25 - 17:40	Q&A and discussion	



16:20 - 17:40	Type: Educational session Title: How should we treat new molecular entities? Moderation: Judith Bovée, Netherlands; Emanuela Palmerini, Italy	Hall B3
16:20 - 16:25	Introduction	
16:25 - 16:40	NTRK rearranged sarcoma <u>Judith Bovée</u> ¹ ; <u>Hans Gelderblom</u> ² , ¹ LUMC-Leiden University Medical Center, Leiden, Netherlands, ² LUMC - Leids Universitair Medisch Centrum, Leiden, Netherlands	
16:40 - 16:55	SMARCA4 deleted undifferentiated tumours <u>Francois Le Loarer</u> ¹ ; <u>Roberta Sanfilippo</u> ² , ¹ Institut Bergonié, Bordeaux, France, ² Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy	
16:55 - 17:10	CIC rearranged sarcoma <u>Eva Wardelmann</u> ¹ ; <u>Emanuela Palmerini</u> ² , ¹ University Hospital Muenster-Gerhard Domagk Institute of Pathology, Muenster, Germany, ² Istituto Ortopedico Rizzoli, Bologna, Italy	
17:10 - 17:25	Sarcoma with BCOR alterations <u>Mehdi Brahmi</u> ¹ ; <u>Khin Thway</u> ² , ¹ Centre Léon Bérard, Lyon, France, ² The Royal Marsden Hospital - NHS Foundation Trust, London, United Kingdom	
17:25 - 17:40	Q&A and discussion	



22.03.2023

09:00 - 10:20 **Type: Educational session** **Hall A**
Title: Update on clinical research in sarcomas
Moderation: Robin Jones, United Kingdom; Urania Dafni, Greece

09:00 - 09:05 **Introduction**

09:05 - 09:20 **Innovative statistical solutions for clinical trials on ultra rare cancers**
Urania Dafni, National and Kapodistrian University of Athens, Athens, Greece

09:20 - 09:35 **Biological intermediate endpoints in clinical trials**
Judith Bliss, ICR - Institute of Cancer Research, London, United Kingdom

09:35 - 09:50 **Bayesian studies for ultra rare cancers**
David Perol, Centre Léon Bérard, Lyon, France

09:50 - 10:05 **Real-world evidence for ultra rare cancers**
Robin Jones, The Royal Marsden Hospital - Chelsea, London, United Kingdom

10:05 - 10:20 **Q&A and discussion**



09:00 - 10:20 **Type: Educational session** **Hall B1**
Title: Rare digestive
 Moderation: Antonia Digkha, Switzerland; Dirk Arnold, Germany

09:00 - 09:05 **Introduction**

09:05 - 09:20 **Rare cancers of pancreas**
Dirk Arnold, Asklepios Tumorzentrum Hamburg AK Altona, Hamburg, Germany

09:20 - 09:35 **Hepatic epithelioid hemangioendothelioma: From local treatments to transplantation and systematic therapies**
Maria Elisa Reig Monzon, Hospital Clinic y Provincial de Barcelona, Barcelona, Spain

09:35 - 09:50 **Small bowel adenocarcinoma: Treat as colon cancer or differently?**
Cornelis Punt, UMC - University Medical Center Utrecht, Utrecht, Netherlands

09:50 - 10:05 **Appendiceal tumours and pseudomyxoma peritonei: From diagnosis to treatment**
Wim Ceelen, UZ Gent - University Hospital Ghent, Gent, Belgium

10:05 - 10:20 **Q&A and discussion**

09:00 - 10:00 **Type: Abstract related session** **Hall B3**
Title: Mini oral session
 Moderation: Agnieszka Kolasinska-Cwikla, Poland; William D. Tap, United States of America

09:00 - 09:05 **47MO - Activating EZH2 mutations define a new subset of aggressive Ewing sarcomas**
Pawel Sobczuk¹; T. Zhang¹; J. Dermawan¹; R.P. Koche¹; P.-J. Hamard¹; P. Jagodzinska-Mucha²; P. Rutkowski²; R. Somwar¹; M. Ladanyi¹, ¹Memorial Sloan Kettering Cancer Center, New York, United States of America, ²Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

09:05 - 09:10 **48MO - Characteristics and outcomes of 76 patients with pleomorphic liposarcoma: The Gustave Roussy experience**
Tarek Assi¹; C. Honoré²; R. Bahleda²; C. Henon³; B. Verret⁴; M. Faron⁴; C. Ngo³; C. Le Pechoux³; A. Levy²; A. Le Cesne², ¹Gustave Roussy - Cancer Campus, COURBEVOIE, France, ²Gustave Roussy - Cancer Campus, Villejuif, France, ³Institut Gustave Roussy, Villejuif, Cedex, France, ⁴Institut Gustave Roussy, Villejuif, France

09:10 - 09:15 **49MO - Atezolizumab and bevacizumab in patients treated with prior atezolizumab in alveolar soft tissue sarcoma (ASPS)**



Alice Chen¹; E. Sharon¹; B. Van Tine²; N. Moore¹; J. Foster¹; J. Glod¹; J. Hu³; C. Rosenberger⁴; G. O'Sullivan Coyne¹; J. Doroshow¹, ¹National Cancer Institute, Bethesda, United States of America, ²Washington University School of Medicine in St. Louis, St. Louis, United States of America, ³USC - University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, United States of America, ⁴National Cancer Institute, Rockville, United States of America

09:15 - 09:20 **124MO - A single centre experience of patients with rare cancers referred for early phase clinical trials**

Angelos Angelakas; N. Cook; D. Graham; M. Krebs; F. Thistlethwaite; L. Carter, The Christie NHS Foundation Trust, Manchester, United Kingdom

09:20 - 09:35 **Invited discussant**

William D. Tap, MSKCC - Memorial Sloan Kettering Cancer Center, New York, United States of America

09:35 - 09:40 **28MO - Predictive biomarkers of response to axitinib in patients with advanced EP-NETs enrolled in the AXINET trial (GETNE 1107): Underlying molecular mechanisms**

Alberto Lens-Pardo¹; C. Carretero-Puche¹; B. Antón Pascual²; J. Capdevila Castillon³; M. Benavent⁴; P. Jimenez Fonseca⁵; E. Grande Pulido⁶; C. Perna⁷; A. Caminoa⁷; B. Rubio-Cuesta¹; J. Sarmentero¹; B. Gil-Calderón¹; B. Soldevilla¹; R. Garcia-Carbonero⁸, ¹Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12) and CNIO, Madrid, Spain, ²Hospital Universitario Doce de Octubre, Madrid, Spain, ³Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain, ⁴Hospital Universitario Virgen del Rocío and IBIS, Seville, Spain, ⁵Hospital Universitario Central de Asturias and ISPA, Oviedo, Spain, ⁶M.D. Anderson Cancer Center Madrid, Madrid, Spain, ⁷Hospital Universitario Ramón y Cajal, IRYCIS and Universidad de Alcalá, Madrid, Spain, ⁸Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CNIO, Hospital Universitario Doce de Octubre. Universidad Complutense de Madrid, Madrid, Spain

09:40 - 09:45 **29MO - Germline variants NGS characterization in patients with non-syndromic adrenocortical carcinoma**

Salvatore Grisanti¹; M. Scatolini²; P. Tomaiuolo²; E. Grosso²; V. Basile³; D. Cosentini¹; S. Puglisi³; M. Laganà¹; P. Perotti³; E. Rossini⁴; D. Smussi¹; S. Sigala⁴; M. Volante⁵; A. Berruti¹; M. Terzolo³, ¹Medical Oncology Unit, Brescia, Italy, ²Fondazione Edo ed Elvo Tempia, Biella, Italy, ³University of Turin, S. Luigi Gonzaga Hospital, Orbassano, Italy, ⁴University of Brescia, Brescia, Italy, ⁵University of Turin, Torino, Italy

09:45 - 09:55 **Invited discussant**

Agnieszka Kolasinska-Cwikla, Maria Skłodowska-Curie Institute-Oncology Center, Warsaw, Poland

09:55 - 10:00 **Q&A**



10:20 - 10:50	Type: Coffee break Title: Coffee break	Foyer (Ground floor)
10:50 - 12:10	Type: Educational session Title: Selecting patients, therapeutics and sequence in immunotherapy of sarcomas Moderation: Noel de Miranda, Netherlands; Robin Jones, United Kingdom	Hall A
10:50 - 10:55	Introduction	
10:55 - 11:10	The immune microenvironment in sarcomas <u>Noel De Miranda</u> , LUMC-Leiden University Medical Center, Leiden, Netherlands	
11:10 - 11:25	Immunotherapy for sarcomas: How to select patients - The use of the sarcoma immunoscore and TLS <u>Antoine Italiano</u> , Institute Bergonié, Bordeaux, France	
11:25 - 11:40	Immunotherapy for sarcomas: How to select the best combination <u>Andrea Napolitano</u> , The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, United Kingdom	
11:40 - 11:55	Immunotherapy for sarcomas: Neoadjuvant or adjuvant? <u>Javier Martin-Broto</u> , Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain	
11:55 - 12:10	Q&A and discussion	



10:50 - 12:10 **Type: Clinical Guidelines session** **Hall B1**
Title: ESMO Clinical Practice Guidelines session
Moderation: Cristiana Sessa, Switzerland; Jean-Yves Blay, France

10:50 - 10:55 **Introduction**

10:55 - 11:05 **Salivary gland tumours: Clinical case**
Francois Regis Ferrand, Ecole Val de Grace, Paris, France

11:05 - 11:15 **Salivary gland tumours: Discussant**
Caroline Even, Institut Gustave Roussy, Villejuif, Cedex, France

11:15 - 11:20 **Q&A and discussion**

11:20 - 11:30 **Biliary tract cancer: Clinical case**
H eloise Bourien, Centre Eugene - Marquis, Rennes, France

11:30 - 11:40 **Biliary tract cancer: Discussant**
Julien Edeline, Centre Eugene - Marquis, Rennes, France

11:40 - 11:45 **Q&A and discussion**

11:45 - 11:55 **Testicular cancer: Clinical case**
Daniele Raggi, IRCCS Ospedale San Raffaele, Milan, Italy

11:55 - 12:05 **Testicular cancer: Discussant**
Patrizia Giannatempo, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

12:05 - 12:10 **Q&A and discussion**



10:50 - 12:10	Type: Educational session Title: Artificial Intelligence and the use of big data Moderation: Sandro Pasquali, Italy; Matthew Blackledge, United Kingdom	Hall B3
10:50 - 10:55	Introduction	
10:55 - 11:10	Radiomics in sarcomas: Where do we stand? <u>Matthew Blackledge</u> , ICR - Institute of Cancer Research, London, United Kingdom	
11:10 - 11:25	AI in digital pathology: Where do we stand? <u>Sebastian Foersch</u> , Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany	
11:25 - 11:40	Big (FAIR) data in sarcoma to build prediction models: perSARC <u>Michiel Van De Sande</u> , Leiden University Medical Center, Leiden, Netherlands	
11:40 - 11:55	Big (FAIR) data in sarcoma to build prediction models: SARCulator <u>Sandro Pasquali</u> , Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, Italy	
11:55 - 12:10	Q&A and discussion	